Showing 715 results
-
Media Release /Kesimpta reduced the risk of disability progression independent of relapse activity (PIRA) by up to almost 60% vs first-line teriflunomide in a subgroup of newly diagnosed, treatment-naïve patients…
-
Media Release /New post hoc data from the Phase III EXPAND trial showed combined high levels of plasma neurofilament light chain (NfL) and plasma glial fibrillary acidic protein (GFAP) were consistently…
-
Media Release /
-
Media Release /Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment EAST HANOVER, N.J., April 12, 2021…
-
Media Release /The STEP (Solutions to Empower Patients) ProgramTM supports the development of creative new approaches to reimagine care Recipients will launch variety of initiatives to help caregivers of people…
-
Media Release /
-
Media Release /Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (…
-
Media Release /Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic idiopathic urticaria (CIU) in patients with an inadequate response to H1 anthistamines1 Currently…
-
Media Release /
-
Media Release /The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval…
